Katja Krockenberger
Papers
1
Total Citations
16
H-Index
1
About
Katja Krockenberger is a leading radiation oncologist whose research focuses on advancing stereotactic body radiotherapy (SBRT) for prostate cancer, with a particular emphasis on hypo-fractionated treatment regimens that reduce patient burden while maintaining efficacy. Her major contributions include pioneering the first German bi-center feasibility trial of hypo-fractionated SBRT for localized prostate cancer, demonstrating that ultra-short, high-dose radiation courses could be safely delivered with minimal toxicity. This work, published in 2017 and cited 16 times, challenged conventional fractionation schedules by showing that non-invasive treatment could be compressed from weeks into just a few sessions—a paradigm shift that improves patient convenience and healthcare resource utilization. Krockenberger’s research has helped validate SBRT as a standard option for low- and intermediate-risk prostate cancer, influencing clinical guidelines in Germany and beyond. Her notable achievement includes leading this multi-institutional trial that established safety benchmarks for dose escalation, paving the way for broader adoption of hypo-fractionation. By bridging feasibility and clinical practice, Krockenberger’s work continues to shape modern radiotherapy, offering patients shorter, more tolerable treatments without compromising oncological outcomes.
Research Focus
Key Achievements
Top Papers
- 1